Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Publications

Post-acute COVID-19 neuropsychiatric symptoms are not associated with ongoing nervous system injury.

Taquet M. et al, (2024), Brain Commun, 6

GRIN2A (NR2A): a gene contributing to glutamatergic involvement in schizophrenia.

Harrison PJ. and Bannerman DM., (2023), Mol Psychiatry

Acute blood biomarker profiles predict cognitive deficits 6 and 12 months after COVID-19 hospitalization.

Taquet M. et al, (2023), Nat Med

Sex and age effects on risk of non-traumatic subarachnoid hemorrhage: retrospective cohort study of 124,234 cases using electronic health records

Harrison C. et al, (2023), Journal of Stroke and Cerebrovascular Diseases

Data-driven Taxonomy for Antipsychotic Medication: A New Classification System

McCutcheon R., (2023), Biological Psychiatry

Bipolar symptoms and lithium treatment affect neural signatures of adaptation of risk-taking to past outcomes during reward-guided decision-making

Scholl J. et al, (2023)

Neuropsychiatric disorders following SARS-CoV-2 infection

HARRISON P. and Taquet M., (2023), Brain

Little evidence supports gabapentinoid use in bipolar disorder or insomnia

Saul H. et al, (2022), BMJ (Clinical research ed.), 379

Incidence of Epilepsy and Seizures Over the First 6 Months After a COVID-19 Diagnosis: A Retrospective Cohort Study.

Taquet M. et al, (2022), Neurology

Glutamatergic dysfunction leads to a hyper-dopaminergic phenotype through deficits in short-term habituation: a mechanism for aberrant salience.

PANAGI M. et al, (2022), Molecular Psychiatry

CACNA1C (CaV1.2) and other L-type calcium channels in the pathophysiology and treatment of psychiatric disorders: Advances from functional genomics and pharmacoepidemiology.

Harrison PJ. et al, (2022), Neuropharmacology

Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients.

Taquet M. et al, (2022), Lancet Psychiatry

New drug targets in psychiatry: Neurobiological considerations in the genomics era.

Harrison PJ. et al, (2022), Neurosci Biobehav Rev, 139

Response to the letter by Lin et al.

Taquet M. et al, (2022), Brain Behav Immun, 104

Impact of the COVID-19 Pandemic on the Global Delivery of Mental Health Services and Telemental Health: Systematic Review.

Zangani C. et al, (2022), JMIR Ment Health

Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.

Taquet M. et al, (2022), Brain Behav Immun, 103, 154 - 162

Using a Generative Model of Affect to Characterize Affective Variability and its Response to Treatment in Bipolar Disorder

PULCU E. et al, (2022), Proceedings of the National Academy of Sciences of USA

Brain-penetrant calcium channel blockers are associated with a reduced incidence of neuropsychiatric disorders.

HARRISON P. and COLBOURNE C., (2022), Molecular Psychiatry

Restricting the spread of SARS-CoV-2 or safeguarding mental health: a false dichotomy?

Taquet M. and Harrison PJ., (2022), Lancet Public Health, 7, e392 - e393

Catechol-O-methyltransferase activity does not influence emotional processing in men

Martens MAG. et al, (2022), Journal of Psychopharmacology, 026988112210890 - 026988112210890

Load More

1
2
3
4
5
6
7
...
»